Insulet Co. (NASDAQ:PODD) SVP Michael P. Spears sold 7,774 shares of the stock in a transaction dated Friday, May 18th. The stock was sold at an average price of $87.77, for a total transaction of $682,323.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Michael P. Spears also recently made the following trade(s):
- On Tuesday, May 15th, Michael P. Spears sold 8,114 shares of Insulet stock. The stock was sold at an average price of $86.64, for a total transaction of $702,996.96.
Insulet opened at $93.15 on Friday, MarketBeat.com reports. The company has a market cap of $5.14 billion, a price-to-earnings ratio of -202.50 and a beta of 1.39. Insulet Co. has a one year low of $40.92 and a one year high of $94.25. The company has a current ratio of 5.48, a quick ratio of 5.16 and a debt-to-equity ratio of 3.34.
Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, May 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.08. The firm had revenue of $123.60 million for the quarter, compared to the consensus estimate of $121.76 million. Insulet had a negative net margin of 4.82% and a negative return on equity of 20.02%. The business’s revenue was up 21.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.17) earnings per share. analysts anticipate that Insulet Co. will post -0.2 EPS for the current year.
A number of brokerages have recently issued reports on PODD. Piper Jaffray Companies increased their price target on shares of Insulet from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, May 3rd. Northland Securities reaffirmed a “buy” rating and issued a $100.00 target price on shares of Insulet in a research note on Friday, May 4th. Canaccord Genuity raised their target price on shares of Insulet from $96.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday. Zacks Investment Research raised shares of Insulet from a “sell” rating to a “buy” rating and set a $94.00 target price on the stock in a research note on Tuesday, May 8th. Finally, Berenberg Bank assumed coverage on shares of Insulet in a research note on Friday, April 20th. They issued a “buy” rating and a $100.00 target price on the stock. Five investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $88.71.
Several hedge funds have recently bought and sold shares of PODD. Millennium Management LLC raised its stake in shares of Insulet by 154.1% during the fourth quarter. Millennium Management LLC now owns 941,567 shares of the medical instruments supplier’s stock worth $64,968,000 after acquiring an additional 571,082 shares in the last quarter. Eagle Asset Management Inc. purchased a new position in shares of Insulet during the first quarter worth approximately $47,002,000. Renaissance Technologies LLC raised its stake in shares of Insulet by 328.2% during the fourth quarter. Renaissance Technologies LLC now owns 661,200 shares of the medical instruments supplier’s stock worth $45,623,000 after acquiring an additional 506,800 shares in the last quarter. Fred Alger Management Inc. raised its stake in shares of Insulet by 32.5% during the fourth quarter. Fred Alger Management Inc. now owns 1,808,616 shares of the medical instruments supplier’s stock worth $124,795,000 after acquiring an additional 443,970 shares in the last quarter. Finally, Rockefeller Capital Management L.P. purchased a new position in shares of Insulet during the first quarter worth approximately $38,007,000.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.